{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:12:08Z","timestamp":1773101528084,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the efficacy and safety of upadacitinib (UPA), an oral Janus kinase inhibitor, as monotherapy or in combination with non-biologic DMARDs (nbDMARDs) in patients with PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Pooled data were analysed from patients with prior inadequate response or intolerance to one or more nbDMARD (SELECT-PsA 1) or one or more biologic DMARD (SELECT-PsA 2) who received placebo, UPA 15\u2009mg once daily (QD) or UPA 30\u2009mg QD as monotherapy or in combination with two or fewer nbDMARDs for 24\u2009weeks. Efficacy outcomes included achievement of ACR responses, Psoriasis Area and Severity Index responses, minimal disease activity and change from baseline and clinically meaningful improvement in the HAQ Disability Index. Adverse events (AEs) were summarized.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1916 patients were included; 574 (30%) received monotherapy and 1342 (70%) received combination therapy. Placebo-subtracted treatment effects for a 20% improvement in ACR criteria at week 12 were 33.7% (95% CI 24.4, 43.1) and 34.0% (95% CI 27.9, 40.1) for UPA 15\u2009mg QD monotherapy and combination therapy, respectively, and 45.7% (95% CI 36.9, 54.5) and 39.6% (95% CI 33.7, 45.5) for UPA 30\u2009mg QD monotherapy and combination therapy, respectively. Treatment effects for other outcomes were consistent between monotherapy and combination therapy. AE frequency was generally similar for UPA monotherapy and combination therapy, although hepatic disorders and creatine phosphokinase elevation were more common with combination therapy vs monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The efficacy and safety of UPA were generally consistent when administered as monotherapy or in combination with nbDMARDs through 24\u2009weeks, supporting the use of UPA with or without nbDMARDs in PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov (https:\/\/clinicaltrials.gov): SELECT-PsA 1 (NCT03104400), SELECT-PsA 2 (NCT03104374)<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab905","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T22:29:47Z","timestamp":1638311387000},"page":"3257-3268","source":"Crossref","is-referenced-by-count":19,"title":["Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"first","affiliation":[{"name":"School of Medicine, Griffith University , Brisbane, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Lariboisi\u00e8re Hospital, AP-HP, Paris University"},{"name":"Bioscar Inserm U1132 and Universit\u00e9 de Paris, H\u00f4pital Lariboisi\u00e8re"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique"},{"name":"Rheumatology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP, Sorbonne Universit\u00e9 , Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[{"name":"Humanitas San Pio X , Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"Allergy, Immunology and Rheumatology Division, Center for Musculoskeletal Medicine, University of Rochester Medical Center , Rochester, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin L","family":"McDearmon-Blondell","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Lesser","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reva","family":"McCaskill","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Feng","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn K","family":"Anderson","sequence":"additional","affiliation":[{"name":"AbbVie Inc , North Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M","family":"Ruderman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine , Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"2022080317041625900_keab905-B1","first-page":"1251","article-title":"New GRAPPA and EULAR recommendations for the management of psoriatic arthritis","volume":"56","author":"Coates","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2022080317041625900_keab905-B2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022080317041625900_keab905-B3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022080317041625900_keab905-B4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3899\/jrheum.151290","article-title":"Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials","volume":"43","author":"Combe","year":"2016","journal-title":"J Rheumatol"},{"key":"2022080317041625900_keab905-B5","first-page":"S94","article-title":"The role of methotrexate in psoriatic arthritis: what is the evidence?","volume":"33","author":"Ianculescu","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022080317041625900_keab905-B6","doi-asserted-by":"crossref","first-page":"e000181","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"2022080317041625900_keab905-B7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022080317041625900_keab905-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022080317041625900_keab905-B9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.rdc.2019.04.007","article-title":"Should methotrexate have any place in the treatment of psoriatic arthritis?","volume":"45","author":"Ye","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"2022080317041625900_keab905-B10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2022080317041625900_keab905-B11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"2022080317041625900_keab905-B12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022080317041625900_keab905-B13","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"J Rheumatol"},{"key":"2022080317041625900_keab905-B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13075-020-02388-5","article-title":"Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies","volume":"23","author":"Combe","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2022080317041625900_keab905-B15","doi-asserted-by":"crossref","first-page":"e14926","DOI":"10.1111\/dth.14926","article-title":"Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: a meta-analysis of randomized controlled trials","volume":"34","author":"Xie","year":"2021","journal-title":"Dermatol Ther"},{"key":"2022080317041625900_keab905-B16","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1016\/S2665-9913(20)30339-8","article-title":"Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL balance","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2022080317041625900_keab905-B17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022080317041625900_keab905-B18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"2022080317041625900_keab905-B19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","article-title":"Methotrexate mechanism in treatment of rheumatoid arthritis","volume":"86","author":"Friedman","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2022080317041625900_keab905-B20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.4254\/wjh.v9.i26.1092","article-title":"Risk of liver disease in methotrexate treated patients","volume":"9","author":"Conway","year":"2017","journal-title":"World J Hepatol"},{"key":"2022080317041625900_keab905-B21","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2022080317041625900_keab905-B22","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab905\/41966386\/keab905.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/8\/3257\/45226653\/keab905.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/8\/3257\/45226653\/keab905.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T17:07:07Z","timestamp":1659546427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/8\/3257\/6448790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,12,3]]},"published-print":{"date-parts":[[2022,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab905","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2021,12,3]]}}}